MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 581071 | Name: ICI 195739

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ICI 195739 is newer antifungal agents, it inhibit neutrophil random migration, chemotaxis and hexose monophosphate shunt activity and depresse natural killer cell cytoxicity.

Chemical Structure

ICI 195739
ICI 195739
CAS#103961-78-0

Theoretical Analysis

MedKoo Cat#: 581071

Name: ICI 195739

CAS#: 103961-78-0

Chemical Formula: C24H20F6N6O2

Exact Mass: 538.1552

Molecular Weight: 538.45

Elemental Analysis: C, 53.54; H, 3.74; F, 21.17; N, 15.61; O, 5.94

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
ICI 195739; D-0870; D0870; D 0870; DO870; Ici 195739; ICI195739;
IUPAC/Chemical Name
2-(2,4-Difluorophenyl)-1-(3-(4-(2,2,3,3-tetrafluoropropoxy)styryl)-1,2,4-triazol-1-yl)-3-(1,2,4-triazol-1-yl)propan-2-ol
InChi Key
FZEJTXCSLUORDW-FPYGCLRLSA-N
InChi Code
InChI=1S/C24H20F6N6O2/c25-17-4-7-19(20(26)9-17)23(37,10-35-14-31-13-33-35)11-36-15-32-21(34-36)8-3-16-1-5-18(6-2-16)38-12-24(29,30)22(27)28/h1-9,13-15,22,37H,10-12H2/b8-3+
SMILES Code
OC(CN1N=CN=C1)(C2=CC=C(F)C=C2F)CN3N=C(/C=C/C4=CC=C(OCC(F)(F)C(F)F)C=C4)N=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 538.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Urbina JA. Specific treatment of Chagas disease: current status and new developments. Curr Opin Infect Dis. 2001 Dec;14(6):733-41. Review. PubMed PMID: 11964893. 2: Williams KJ, Denning DW. Termination of development of D0870. J Antimicrob Chemother. 2001 May;47(5):720-1. PubMed PMID: 11328795. 3: Molina J, Urbina J, Gref R, Brener Z, Rodrigues Júnior JM. Cure of experimental Chagas' disease by the bis-triazole DO870 incorporated into 'stealth' polyethyleneglycol-polylactide nanospheres. J Antimicrob Chemother. 2001 Jan;47(1):101-4. PubMed PMID: 11152439. 4: Molina J, Brener Z, Romanha AJ, Urbina JA. In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi. J Antimicrob Chemother. 2000 Jul;46(1):137-40. PubMed PMID: 10882704. 5: Matsunaga T, Harada T, Hirata Z, Mitsui T, Murano H, Shibutani Y. D0870, an antifungal agent, induces reverse use-dependent QT prolongation in dogs. J Vet Med Sci. 2000 May;62(5):491-7. PubMed PMID: 10852397. 6: Matsunaga T, Harada T, Mitsui T, Murano H, Duffy PA, Aldridge A, Shibutani Y. Influences of catecholamines on the sudden death induced in dogs by an antifungal agent, D0870. J Electrocardiol. 2000 Apr;33(2):181-8. PubMed PMID: 10819411. 7: Kojima M, Yamada H, Nakamura S, Kikuchi M, Nakanishii T, Takahashi Y, Mochizuki H, Mikami Y. Antifungal activities of D0870 against fluconazole-resistant Candida albicans. Nihon Ishinkin Gakkai Zasshi. 1999;40(4):209-15. Japanese. PubMed PMID: 10536307. 8: Matsunaga T, Harada T, Harada T, Inokuma M, Mitsui T, Duffy PA, Aldridge A, Shibutani Y. QT prolongation and torsades de pointes induced by an antifungal agent, D0870, in conscious dogs. Toxicology. 1999 Feb 15;132(2-3):187-99. PubMed PMID: 10433382. 9: McKillop D, Back DJ, McCormick AD, Evans JA, Tjia J. Preclinical and in vitro assessment of the potential of D0870, an antifungal agent, for producing clinical drug interactions. Xenobiotica. 1999 Apr;29(4):395-408. PubMed PMID: 10375008. 10: Hood SV, Hollis S, Percy M, Atkinson G, Williams K, Denning DW. Assessment of therapeutic response of oropharyngeal and esophageal candidiasis in AIDS with use of a new clinical scoring system: studies with D0870. Clin Infect Dis. 1999 Mar;28(3):587-96. PubMed PMID: 10194083. 11: Yang HC, Mikami Y, Yazawa K, Taguchi H, Nishimura K, Miyaji M, Branchini ML, Aoki FH, Yamamoto K. Colorimetric MTT assessment of antifungal activity of D0870 against fluconazole-resistant Candida albicans. Mycoses. 1998 Dec;41(11-12):477-80. PubMed PMID: 9919890. 12: Yamada H, Tsuda T, Watanabe T, Kusakabe S, Mochizuki H. Antifungal activity of D0870 against murine infections and its mechanism of action. Chemotherapy. 1998 Mar-Apr;44(2):112-20. PubMed PMID: 9551242. 13: De Wit S, O'Doherty E, Edwards J, Yates R, Smith RP, Clumeck AN. Pharmacokinetics of two multiple-dosing regimens of D0870 in human immunodeficiency virus-positive patients: a phase I study. Antimicrob Agents Chemother. 1998 Apr;42(4):903-6. PubMed PMID: 9559805; PubMed Central PMCID: PMC105564. 14: Liendo A, Lazardi K, Urbina JA. In-vitro antiproliferative effects and mechanism of action of the bis-triazole D0870 and its S(-) enantiomer against Trypanosoma cruzi. J Antimicrob Chemother. 1998 Feb;41(2):197-205. PubMed PMID: 9533461. 15: Cartledge JD, Denning DW, Dupont B, Clumeck N, De Wit S, Midgley J, Hawkins DA, Gazzard BG. Treatment of HIV-related fluconazole-resistant oral candidosis with D0870, a new triazole antifungal. AIDS. 1998 Mar 5;12(4):411-6. PubMed PMID: 9520171. 16: Yamada H, Watanabe T, Kato K, Mochizuki H. Fungicidal mechanism of action of D0870 against Cryptococcus neoformans under acidic conditions. Antimicrob Agents Chemother. 1997 Dec;41(12):2710-3. PubMed PMID: 9420043; PubMed Central PMCID: PMC164193. 17: Koltin Y, Hitchcock CA. The search for new triazole antifungal agents. Curr Opin Chem Biol. 1997 Aug;1(2):176-82. Review. PubMed PMID: 9667858. 18: Fidel PL Jr, Cutright JL, Sobel JD. Efficacy of D0870 treatment of experimental Candida vaginitis. Antimicrob Agents Chemother. 1997 Jul;41(7):1455-9. PubMed PMID: 9210665; PubMed Central PMCID: PMC163939. 19: Venkateswarlu K, Denning DW, Kelly SL. In-vitro activity of D0870, a new triazole antifungal drug, in comparison with fluconazole and itraconazole against Aspergillus fumigatus and Candida krusei. J Antimicrob Chemother. 1997 Jun;39(6):731-6. PubMed PMID: 9222042. 20: De Wit S, Dupont B, Cartledge JD, Hawkins DA, Gazzard BG, Clumeck N, Denning DW. A dose comparison study of a new triazole antifungal (D0870) in HIV-positive patients with oral candidiasis. AIDS. 1997 May;11(6):759-63. PubMed PMID: 9143608.